Business Description
Betta Pharmaceuticals Co Ltd
ISIN : CNE100002DD9
Share Class Description:
SZSE:300558: Class ACompare
Compare
Traded in other countries / regions
300558.China IPO Date
2016-11-07Description
Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.22 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.45 | |||||
| Debt-to-EBITDA | 5.65 | |||||
| Interest Coverage | 9.08 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.44 | |||||
| Beneish M-Score | -3.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.4 | |||||
| 3-Year EBITDA Growth Rate | -8.5 | |||||
| 3-Year EPS without NRI Growth Rate | -8.9 | |||||
| 3-Year FCF Growth Rate | -64.2 | |||||
| 3-Year Book Growth Rate | 7.8 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.98 | |||||
| 9-Day RSI | 51.58 | |||||
| 14-Day RSI | 46.72 | |||||
| 6-1 Month Momentum % | -18.73 | |||||
| 12-1 Month Momentum % | -33.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.91 | |||||
| Quick Ratio | 0.67 | |||||
| Cash Ratio | 0.39 | |||||
| Days Inventory | 279.94 | |||||
| Days Sales Outstanding | 50.77 | |||||
| Days Payable | 470.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.18 | |||||
| Dividend Payout Ratio | 0.08 | |||||
| 3-Year Dividend Growth Rate | -28.3 | |||||
| Forward Dividend Yield % | 0.18 | |||||
| 5-Year Yield-on-Cost % | 0.16 | |||||
| 3-Year Average Share Buyback Ratio | -0.4 | |||||
| Shareholder Yield % | -5.95 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.91 | |||||
| Operating Margin % | 15.85 | |||||
| Net Margin % | 14.84 | |||||
| FCF Margin % | -3.02 | |||||
| ROE % | 7.6 | |||||
| ROA % | 4.5 | |||||
| ROIC % | 5.27 | |||||
| ROC (Joel Greenblatt) % | 18.11 | |||||
| ROCE % | 6.01 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 42.29 | |||||
| PE Ratio without NRI | 42.2 | |||||
| Shiller PE Ratio | 46.39 | |||||
| PEG Ratio | 3.77 | |||||
| PS Ratio | 6.28 | |||||
| PB Ratio | 2.98 | |||||
| Price-to-Tangible-Book | 8.57 | |||||
| Price-to-Operating-Cash-Flow | 16.33 | |||||
| EV-to-EBIT | 41.56 | |||||
| EV-to-EBITDA | 41.56 | |||||
| EV-to-Revenue | 6.88 | |||||
| EV-to-FCF | -227.91 | |||||
| Price-to-Projected-FCF | 13.75 | |||||
| Price-to-DCF (Earnings Based) | 3.66 | |||||
| Price-to-Graham-Number | 4.01 | |||||
| Earnings Yield (Greenblatt) % | 2.41 | |||||
| FCF Yield % | -0.49 | |||||
| Forward Rate of Return (Yacktman) % | -2.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Betta Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 2,660.352 | ||
| EPS (TTM) (Â¥) | 0.93 | ||
| Beta | 2.28 | ||
| Volatility % | 50.65 | ||
| 14-Day RSI | 46.72 | ||
| 14-Day ATR (Â¥) | 1.529205 | ||
| 20-Day SMA (Â¥) | 39.1005 | ||
| 12-1 Month Momentum % | -33.69 | ||
| 52-Week Range (Â¥) | 33.11 - 73.11 | ||
| Shares Outstanding (Mil) | 418.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Betta Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Betta Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Betta Pharmaceuticals Co Ltd Frequently Asked Questions
What is Betta Pharmaceuticals Co Ltd(SZSE:300558)'s stock price today?
The current price of SZSE:300558 is ¥39.11. The 52 week high of SZSE:300558 is ¥73.11 and 52 week low is ¥33.11.
When is next earnings date of Betta Pharmaceuticals Co Ltd(SZSE:300558)?
The next earnings date of Betta Pharmaceuticals Co Ltd(SZSE:300558) is .
Does Betta Pharmaceuticals Co Ltd(SZSE:300558) pay dividends? If so, how much?
The Dividend Yield %  of Betta Pharmaceuticals Co Ltd(SZSE:300558) is 0.18% (As of Today), Highest Dividend Payout Ratio of Betta Pharmaceuticals Co Ltd(SZSE:300558) was 3.57. The lowest was 0.08. And the median was 0.28. The  Forward Dividend Yield % of Betta Pharmaceuticals Co Ltd(SZSE:300558) is 0.18%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers